<DOC>
	<DOCNO>NCT00222729</DOCNO>
	<brief_summary>The purpose study determine combination two new drug pemetrexed ( Alimta ) bevacizumab ( Avastin ) increase effectiveness treatment head neck cancer . Currently pemetrexed approve Food Drug Administration ( FDA ) another type cancer , mesothelioma , approve head neck cancer .</brief_summary>
	<brief_title>Study Pemetrexed Bevacizumab Patients With Head Neck Cancer</brief_title>
	<detailed_description>Main objective study 1 ) evaluate time progression ( primary endpoint ) combination pemetrexed bevacizumab recurrent metastatic head neck cancer ; 2 ) evaluate objective response rate , duration response , overall survival , toxicity associate therapy 3 ) collect tumor tissue previous diagnostic procedure blood specimen prospectively , therapy , future correlative study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Metastatic locally recurrent squamous cell carcinoma head neck . Patients local recurrence consider incurable mean locoregional therapy , judge investigator . 2 . Cytologically histologically confirm squamous cell carcinoma . Nasopharyngeal carcinoma histologic subtype WHO II III exclude . 3 . Unidimensional measurable disease ( RECIST criterion ) . If site measurable disease previously irradiate area , patient must document progression disease area . 4 . ECOG performance status 01 . 5 . Full recover effect prior surgery , radiation therapy . A minimum time period 3 week elapse completion extensive radiation therapy recurrent/metastatic disease enrollment study 6 . Laboratory value : ANC ³ 1500/mm³ . Platelets ³ 100,000/mm³ . Total Bilirubin within normal institutional limit . 7 . Transaminases ( AST ALT ) &lt; 3 x ULN . Creatinine clearance 45 ml/min high calculate use CockcroftGault formula . 8 . Urine protein creatinine ( UPC ) ratio ≤ 1.0 spot urine urinalysis . 9 . Age &gt; 18 year capacity give inform consent . 1 . Prior chemotherapy biologic therapy recurrent/metastatic head neck cancer . 2 . Prior pemetrexed , bevacizumab , antiangiogenesis agent time . 3 . Presence tumor invade major vessel . 4 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment , anticipation need major surgical procedure course study 5 . Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior study enrollment . 6 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior registration . Serious nonhealing wound , ulcer , bone fracture . 7 . History brain metastasis seizure . 8 . Prior malignancy , exception curatively treat squamous cell basal carcinoma skin situ cervical cancer , unless 5year diseasefree interval . 9 . Preexisting peripheral neuropathy &gt; grade 2 . 10 . Myocardial infarction stroke last 6 month . Unstable angina ; Heart Association ( NYHA ) Grade II great congestive heart failure ; Clinically significant peripheral vascular disease ; CNS cerebrovascular ischemia within last 6 month ; active serious infection ; coexist medical condition would preclude full compliance study 11 . Bleeding diathesis coagulopathy . 12 . Therapeutic anticoagulation ( prophylactic use warfarin 1 mg per day allow ) INR great 1.5 registration 13 . History gross hemoptysis ( define bright red blood ½ teaspoon ) . 14 . Uncontrolled hypertension ( &gt; 150/100 ) 15 . Pregnant lactating . 16 . Use NSAIDs within 5 day protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>head</keyword>
	<keyword>neck</keyword>
</DOC>